Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: Dual-Affinity Re-Targeting anticancer therapeutics - MacroGenics

Drug Profile

Research programme: Dual-Affinity Re-Targeting anticancer therapeutics - MacroGenics

Alternative Names: 5T4 x CD3 DART; DART candidates - MacroGenics/Pfizer; DART Oncology; EphA2xCD3 DART; IL1Ra2xCD3 DART; JNJ-9383; MGD 015; MGD-15; ROR1xCD3 DART

Latest Information Update: 13 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MacroGenics
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies; Proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; CD3 antigen modulators; Cytotoxic T-lymphocyte antigen 4 inhibitors; Interleukin 13 receptor modulators; Programmed cell death-1 receptor antagonists; Receptor tyrosine kinase-like orphan receptor modulators; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 06 Dec 2018 MacroGenics in-licenses the Trianni Mouse transgenic mouse platform technology from Trianni
  • 03 Dec 2018 MacroGenics plans a phase I trial for MGD 019 for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in the US in December 2018 (NCT03761017)
  • 03 Dec 2018 Preclinical development is ongoing in the US (NCT03761017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top